Literature DB >> 6339294

An overview of two comparative multicentre trials with halometasone/triclosan cream in acute superficial bacterial skin infections.

A Aliaga, A Castells, D Kriznik, J Lalosević, J Marrón, J Moragas, J Ocaña, C Schindléry.   

Abstract

Two multicentre, open comparative trials were carried out by seven dermatologists in Spain and Yugoslavia in 220 evaluable patients with acute superficial skin infections. In these trials halometasone/triclosan cream showed an overall success rate ('good' and 'very good' results) of 84% as against 60% obtained with the comparative preparations. With regard to therapeutic effect halometasone/triclosan cream proved significantly superior to fluocinolone acetonide/neomycin cream (p less than 0.001) and yielded a higher overall success rate, although not statistically significant, than that observed with fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream (75% versus 57%). The halometasone/triclosan cream was well tolerated: the incidence of unwanted effects was significantly lower (p less than 0.05) than that with fluocinolone acetonide/neomycin cream and equal to that with fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339294

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

Review 1.  Triclosan: An Update on Biochemical and Molecular Mechanisms.

Authors:  Mohammad A Alfhili; Myon-Hee Lee
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

2.  Evaluation of Efficacy, Safety, and Tolerability of Fixed Dose Combination (FDC) of Halometasone 0.05% and Fusidic Acid 2% W/W Topical Cream Versus FDC of Betamethasone Valerate 0.12% and Neomycin Sulphate 0.5% W/W Topical Cream in the Treatment of Infected Eczematous Dermatosis in Indian Subjects: A Randomized Open-Label Comparative Phase III Multi-Centric Trial.

Authors:  Dasiga Venkata Subrahmanya Pratap; Mariam Philip; Narayana T Rao; Hemangi R Jerajani; Sainath A Kumar; Maria Kuruvila; Latha S Moodahadu; Shilpi Dhawan
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.